![Nigel Raymond Stevenson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Nigel Raymond Stevenson
Direttore Tecnico/Scientifico/R&S presso VIVOS INC.
Profilo
Nigel Raymond Stevenson is the founder of TcNet LLC.
He currently holds the position of Chief Science Officer at Vivos, Inc. and Chief Operating Officer at Exubrion Therapeutics, Inc. Nigel has previously worked as Vice President-Production & Research at Theragenics Corp., Chief Operating Officer at Clear Vascular, Inc., Chief Operating Officer at Trace Life Sciences, Inc., and Head-Isotope Production & Research at Tri University Mezzon Facility.
Nigel obtained his doctorate degree from the University of London in 1983.
Posizioni attive di Nigel Raymond Stevenson
Società | Posizione | Inizio |
---|---|---|
VIVOS INC. | Direttore Tecnico/Scientifico/R&S | - |
TcNet LLC | Amministratore Delegato | - |
Exubrion Therapeutics , Inc.
![]() Exubrion Therapeutics , Inc. Medical SpecialtiesHealth Technology Exubrion Therapeutics, Inc. develops electron therapeutic veterinary devices. The company is based in Buford, GA. The company was founded by Dennis F. Steadman. The CEO is Peter Selover. | Direttore operativo | 01/01/2019 |
Precedenti posizioni note di Nigel Raymond Stevenson
Società | Posizione | Fine |
---|---|---|
Tri University Mezzon Facility
![]() Tri University Mezzon Facility Miscellaneous Commercial ServicesCommercial Services Tri University Mezzon Facility provides subatomic physics laboratories. The firm’s technical services include beamlines, information systems & technology, science-technology, diagnostics group, engineering, operations, ATG and radiation protection. The company was founded in 1968 and is headquartered in Vancouver, CA. | Corporate Officer/Principal | - |
Trace Life Sciences, Inc.
![]() Trace Life Sciences, Inc. Chemicals: SpecialtyProcess Industries Trace Life Sciences, Inc. manufactures radiochemical, radiopharmaceuticals and research isotopes for medical imaging and therapy. The firm produces radiopharmaceutical and radiochemical isotopes used in nuclear medicine to diagnose ischemia, mycocardial infarction, and molecular imaging. The compnay is headquartered in Denton, TX. | Direttore operativo | - |
Theragenics Corp.
![]() Theragenics Corp. Medical SpecialtiesHealth Technology Theragenics Corp. develops, manufactures and markets medical devices. It offers wound closure, vascular access, and specialty needle products. The company was founded in 1981 and is headquartered in Buford, GA. | Corporate Officer/Principal | - |
Clear Vascular, Inc.
![]() Clear Vascular, Inc. Pharmaceuticals: MajorHealth Technology Clear Vascular, Inc. develops radionuclide products for multiple clinical applications. The firm has developed an injectable, targeted radiopharmaceutical agent, Tin-Annexin, for imaging and therapy of inflammatory tissues, initially targeting vulnerable and unstable plaque. It is a private radiopharmaceutical company developing a unique radionuclide for multiple clinical applications including diagnosis and therapy. The company was founded by Gilbert R. Gonzales in 2005 and is headquartered in Austin, TX. | Direttore operativo | - |
Formazione di Nigel Raymond Stevenson
University of London | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
VIVOS INC. | Health Technology |
Aziende private | 6 |
---|---|
Theragenics Corp.
![]() Theragenics Corp. Medical SpecialtiesHealth Technology Theragenics Corp. develops, manufactures and markets medical devices. It offers wound closure, vascular access, and specialty needle products. The company was founded in 1981 and is headquartered in Buford, GA. | Health Technology |
Clear Vascular, Inc.
![]() Clear Vascular, Inc. Pharmaceuticals: MajorHealth Technology Clear Vascular, Inc. develops radionuclide products for multiple clinical applications. The firm has developed an injectable, targeted radiopharmaceutical agent, Tin-Annexin, for imaging and therapy of inflammatory tissues, initially targeting vulnerable and unstable plaque. It is a private radiopharmaceutical company developing a unique radionuclide for multiple clinical applications including diagnosis and therapy. The company was founded by Gilbert R. Gonzales in 2005 and is headquartered in Austin, TX. | Health Technology |
Trace Life Sciences, Inc.
![]() Trace Life Sciences, Inc. Chemicals: SpecialtyProcess Industries Trace Life Sciences, Inc. manufactures radiochemical, radiopharmaceuticals and research isotopes for medical imaging and therapy. The firm produces radiopharmaceutical and radiochemical isotopes used in nuclear medicine to diagnose ischemia, mycocardial infarction, and molecular imaging. The compnay is headquartered in Denton, TX. | Process Industries |
Tri University Mezzon Facility
![]() Tri University Mezzon Facility Miscellaneous Commercial ServicesCommercial Services Tri University Mezzon Facility provides subatomic physics laboratories. The firm’s technical services include beamlines, information systems & technology, science-technology, diagnostics group, engineering, operations, ATG and radiation protection. The company was founded in 1968 and is headquartered in Vancouver, CA. | Commercial Services |
TcNet LLC | |
Exubrion Therapeutics , Inc.
![]() Exubrion Therapeutics , Inc. Medical SpecialtiesHealth Technology Exubrion Therapeutics, Inc. develops electron therapeutic veterinary devices. The company is based in Buford, GA. The company was founded by Dennis F. Steadman. The CEO is Peter Selover. | Health Technology |
- Borsa valori
- Insiders
- Nigel Raymond Stevenson